247 related articles for article (PubMed ID: 24423353)
1. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011.
Layton JB; Li D; Meier CR; Sharpless JL; Stürmer T; Jick SS; Brookhart MA
J Clin Endocrinol Metab; 2014 Mar; 99(3):835-42. PubMed ID: 24423353
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
[TBL] [Abstract][Full Text] [Related]
3. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
4. Comparative Safety of Testosterone Dosage Forms.
Layton JB; Meier CR; Sharpless JL; Stürmer T; Jick SS; Brookhart MA
JAMA Intern Med; 2015 Jul; 175(7):1187-96. PubMed ID: 25962056
[TBL] [Abstract][Full Text] [Related]
5. Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013.
Layton JB; Kim Y; Alexander GC; Emery SL
JAMA; 2017 Mar; 317(11):1159-1166. PubMed ID: 28324090
[TBL] [Abstract][Full Text] [Related]
6. Word of wisdom. Re: testosterone lab testing and initiation in the United kingdom and the United States, 2000 to 2011.
Scovell JM; Ramasamy R; Lipshultz LI
Eur Urol; 2014 Oct; 66(4):786-7. PubMed ID: 25218074
[No Abstract] [Full Text] [Related]
7. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
8. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
[TBL] [Abstract][Full Text] [Related]
9. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.
Budoff MJ; Ellenberg SS; Lewis CE; Mohler ER; Wenger NK; Bhasin S; Barrett-Connor E; Swerdloff RS; Stephens-Shields A; Cauley JA; Crandall JP; Cunningham GR; Ensrud KE; Gill TM; Matsumoto AM; Molitch ME; Nakanishi R; Nezarat N; Matsumoto S; Hou X; Basaria S; Diem SJ; Wang C; Cifelli D; Snyder PJ
JAMA; 2017 Feb; 317(7):708-716. PubMed ID: 28241355
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study.
Loo SY; Azoulay L; Nie R; Dell'Aniello S; Yu OHY; Renoux C
Am J Med; 2019 Sep; 132(9):1069-1077.e4. PubMed ID: 30953635
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
12. Review of Testim gel.
McNicholas T; Ong T
Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
Mechlin CW; Frankel J; McCullough A
J Sex Med; 2014 Jan; 11(1):254-61. PubMed ID: 24119010
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
Rhoden EL; Morgentaler A
J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
[TBL] [Abstract][Full Text] [Related]
15. Late-Onset Hypogonadism and Testosterone Replacement in Older Men.
Bhattacharya RK; Bhattacharya SB
Clin Geriatr Med; 2015 Nov; 31(4):631-44. PubMed ID: 26476121
[TBL] [Abstract][Full Text] [Related]
16. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost.
Taylor F; Levine L
J Sex Med; 2010 Jan; 7(1 Pt 1):269-76. PubMed ID: 19694928
[TBL] [Abstract][Full Text] [Related]
17. A UK epidemic of testosterone prescribing, 2001-2010.
Gan EH; Pattman S; H S Pearce S; Quinton R
Clin Endocrinol (Oxf); 2013 Oct; 79(4):564-70. PubMed ID: 23480258
[TBL] [Abstract][Full Text] [Related]
18. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
Dobs A; Norwood P; Potts S; Gould E; Chitra S
J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
